The Cutting Edge in Addiction Treatment: Long-Acting Injectables
Tuesday, May 20, 2025
2:15 PM – 3:15 PM
CE: 1.00 AAPA Category 1 CME
No relevant relationships with ineligible companies to disclose within the past 24 months.
Long-acting injectable (LAI) formulations represent a significant advancement in addiction treatment, addressing key challenges of daily oral medications. This presentation explores the use of LAIs, specifically buprenorphine for opioid use disorder (OUD) and naltrexone for alcohol use disorder (AUD). We will discuss the pharmacology, efficacy, and safety profiles of these medications, comparing delivery systems. The presentation will cover patient selection criteria, integration into comprehensive treatment plans, and potential barriers to implementation. Case studies will illustrate real-world applications and outcomes. Emerging trends and ongoing research in LAIs will also be highlighted.
Learning Objectives:
At the conclusion of this session, participants should be able to:
Analyze pharmacological differences between long-acting injectable formulations of buprenorphine and naltrexone for treating opioid use disorder and alcohol use disorder
Evaluate the benefits and limitations of long-acting injectables compared to oral medications in improving treatment outcomes for patients with SUDs
Formulate a patient-centered treatment plan that incorporates long-acting injectable medications within a comprehensive addiction management approach
